Taro Inaba
Founder and Managing Partner @ Remiges Ventures
Tokyo, Japan
Taro Inaba is a Founder and Managing Partner at Remiges Ventures. He Attended European University.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Taro Inaba invests in
Stages Taro Inaba invests in
Countries Taro Inaba invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (75%)
- Life Science 2 (50%)
- Medical 1 (25%)
- Health Care 1 (25%)
- Pharmaceutical 1 (25%)
Stage
- Series A 2 (50%)
- Seed 1 (25%)
- Series B 1 (25%)
Country
- United States 2 (50%)
- Japan 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| LUCA Science develops innovative treatments intended for mitochondrial and related diseases. | $29.2M / Series B / Jun 06, 2022 | ||
| Capacity Bio is a therapeutics company that is focused on mitophagy. Capacity Bio is developing the most comprehensive and advanced mitophagy therapeutics and development platform for the purpose of restoring mitochondrial quality control in disease. | Seed / Jan 01, 2022 | ||
| LUCA Science develops innovative treatments intended for mitochondrial and related diseases. | $9.8M / Series A / Sep 01, 2020 | ||
| Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide. Founded on groundbreaking neuro-immunology research from the laboratoryof Professor Edgar Engleman, MD, at Stanford University, Tranquis’ novel therapeutic approach targets underlying myeloid immune cell dysfunction that has been linked to a variety of nervous system disorders. The company’s portfolio is comprised of small molecules which cross the blood-brain barrier, and the lead therapeutic candidate has demonstrated highly encouraging effects in challenging preclinical models of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s Disease (PD), and age-related cognitive impairment. Tranquis plans to initiate development in orphan neurodegenerative diseases such as ALS and FTD and later expand into more prevalent diseases such as PD and Alzheimer’s Disease. | $30M / Series A / Jul 09, 2020 |
Co-Investors
About Remiges Ventures
Remiges Ventures is a venture capital firm that focuses on groups and businesses in the Japanese academia and pharmaceutical industry.
Remiges Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Taro Inaba
Founder and Managing Partner
|
|||
Takahide Koda
Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Taro Inaba invest in?
Taro Inaba invests primarily in Biotechnology, Life Science and Medical startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Taro Inaba?
Public channels for Taro Inaba include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Taro Inaba last invest?
The most recent investment recorded for Taro Inaba closed in Jun 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
